{"prompt": "['EudraCT Number 2019-002880-82, IRAS Number 1003208', 'Women recruited into GUARD will subsequently be offered the opportunity to', 'participate in the GUARD MEC sub study. Women with a clinical diagnosis of GDM who do', 'not require medication to control the condition, and pregnant women without GDM, will be', 'invited to participate in the GUARD MEC only.', '6.4 Randomisation Procedure / Code Break', 'Allocation of treatment arm will be randomised by secure computerised web-based', 'programme, provided by MedSciNetLtd. The groups will be minimised by;', '*', 'BMI category (25-29.9, 30-34.9, >35),', 'Previous history of GDM,', '*', 'Disease severity (baseline fasting glucose <6.2 or 6.2),', '* Centre', 'Regular checks during the recruitment phase will be carried out to confirm that the', 'minimisation procedure has been applied correctly.', 'Once a participant has provided informed written consent, baseline details will be', 'entered into the eCRF. As soon as eligibility has been confirmed, treatment allocation will', 'be assigned via the database, and the study ID created. All parties will be aware of the', \"participants' allocation. The pharmacy department will be informed so they can supply the\", 'appropriate IMP for the participant.', 'Emergency code breaking is not required as the treatment is open label.', '6.5 Withdrawal of Subjects', 'Participants have the right to withdraw from the study at any time for any reason. The', 'investigator also has the right to withdraw patients from the study drug in the event of inter-', \"current illness, AEs, SAE's, SUSAR's, protocol violations, cure, administrative reasons or\", 'other reasons. It is understood by all concerned that an excessive rate of withdrawals can', 'render the study un-interpretable; therefore, unnecessary withdrawal of patients should be', 'avoided. Should a patient decide to withdraw from the study, all efforts will be made to report', 'the reason for withdrawal as thoroughly as possible.', 'Should a patient withdraw from study drug only (and not from trial participation), efforts', 'will be made to continue to obtain follow-up data, with the permission of the patient.', 'Participants who withdraw from trial medication will be asked to confirm whether they are', 'still willing to provide: i) trial specific data, including samples at delivery, ii) data collected as', 'per routine clinical practice.', 'In case of withdrawn participants, they will be asked to return all unused IMP to the', 'study team.', 'GUARD protocol V1.0 11Mar20', 'Page 20 of 53']['EudraCT Number 2019-002880-82, IRAS Number 1003208', 'Patients can withdraw from GUARD MEC and still continue participating in GUARD', 'study.', '6.6 Expected Duration of Trial', 'It is expected that each participant will be in the treatment period for a maximum of', 'approximately 14 weeks, with an additional data point collected 3 months post birth from the', 'local GP (the result of the HbA1c sample only). Participants will be asked for permission to', 'be contacted in the future for follow up of their offspring. Methods of, \"keep in touch\\' such as', 'Christmas cards, newsletters etc, will be used to keep participants engaged after their', 'participation is completed. Any follow up procedures will have all appropriate regulatory', 'approvals in place.', 'The end of the trial will be defined as database lock, once all recruits have completed', 'all the study related visits, and the data has been entered in the eCRF and cleaned.', 'GUARD protocol V1.0 11Mar20', 'Page 21 of 53']['EudraCT Number 2019-002880-82, IRAS Number 1003208', '7. Trial Procedures', 'Visit name & approximate', 'Participant', 'Baseline', 'Follow up', 'Follow up', 'Birth', 'Post-birth', 'pregnancy week', 'identificatio', '1', '2', 'n', '26+0-30+6', '27+0-31+6', '32+0 + 1 b', '3 month', 'a', 'post birth', 'Patient information *', 'Xh', 'Informed consent *', 'X', 'Inclusion / exclusion criteria*', 'X', 'Demographics *', 'X', 'Medical and obstetric', 'X', 'personal and family history', '*', 'Adverse events*', 'X', 'X', 'Xn', 'Concomitant medication *', 'X', 'X', 'X', 'X', 'o', 'Weight *', 'X', 'X', 'Blood pressure and pulse d', 'X', 'X', 'Fasted glucose', 'X', 'u', 'X', 'HbA1c', 'Xi', 'Xj', 'X', 'Xt', 'Liver function tests, bile', 'X', 'X', 'acids and high sensitivity C-', 'reactive protein, U&E', 'Fasting lipid profile', 'X', '1,5-Anhydroglucitol and non-', 'X', 'X', 'fasting metabolic hormones', '1,5-Anhydroglucitol and', 'X', 'fasting free fatty acids &', 'metabolic hormones e', 'Optional faecal sample e', 'X k', 'Optional GUARD MEC', 'X\u00b9', 'Blood samples after a', 'breakfast e *', 'Cord blood samples e', 'Meconium collection e', 'Randomisation', 'X', 'IMP dispensing', 'X', 'X', 'IMP administration', 'X (continuously)', 'Dispense diary card', 'X', 'Drug diary review', 'X', 'X', 'X', 'Continuous Glucose', 'X', 'X', 'X', 'Monitoring f*', 'Download CGM data *', 'X', 'X', 'X', 'Optional vascular studies g', 'X', 'X', 'X', 'Quality of life questionnaires', 'X', 'X', '(EQ-5D-5L)', 'Treatment satisfaction', 'X', 'questionnaires (DTSQs)', '4-day food diary', '*', 'm', 'm', 'Labour and birth data *', 'X p', 'Neonatal anthropometry *', 'qr', 'Neonatal data *', 's', '* - assessments applicable to patients in GUARD MEC, to be done during the GUARD MEC study visit.', 'a - If participants are recruited earlier or later than expected, follow up visits will be adjusted according to', 'clinical pathways and to ensure the participant has been receiving IMP for at least 2 weeks.', 'b - Women must fast for at least 3 hours', 'C - To occur at local GP practice approximately 3 months post-delivery (as per standard of care).', \"d - Blood pressure in triplicate and pulse only for woman who don't consent to the vascular studies. Use non-\", 'dominant arm.', 'GUARD protocol V1.0 11Mar20', 'Page 22 of 53']\n\n###\n\n", "completion": "END"}